Pharmaceutical industry – Page 42
-
Business
UCB sells speciality generics subsidiary
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
Business
Labcorp to buy Covance and enter contract research
Firm wants to diversify away from diagnostics, but law firm investigation suggests investors are unconvinced of the deal’s value
-
Business
Perrigo to buy Omega Pharma for €3.6bn
Deal strengthens Perrigo’s over-the-counter portfolio and pushes strongly into Europe
-
Business
Chinese buyer resurrects US Boehringer plant
UniTao will take over manufacturing site scheduled for closure, saving over 200 jobs
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
BusinessCHF3bn redevelopment for Roche’s Basel site
New buildings will move employees out of rented office space
-
Business
Amgen stacks up additional job cuts
Up to 1100 more staff face redundancy in ongoing restructuring plan
-
Business
Amgen seeks injunction to protect patents
Sanofi and Regeneron sued over cholesterol-regulating antibodies
-
BusinessIndian manufacturers hit back over quality claims
Study showing drugs exported to Africa are substandard prompts backlash from generic drugmakers
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
Business
Endo outbids QLT for Auxilium merger
Biotech backs out of Canadian deal in favour of increased $2.6bn bid from Endo
-
Business
EMA finalises trial transparency rules
Researcher access reinstated, but company redaction rights may cause issues
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic
-
Business
Becton Dickinson to buy CareFusion for $12bn
Medical devices merger continues consolidation trend
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
FeatureTransparency measures forced on pharma
Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical data, writes Nuala Moran
-
Business
Lumara splits and sells to AMAG and Perrigo
Lumara has just emerged from bankruptcy and brings a drug for suppressing pre-term birth, plus other women’s health products
-
Business
India backs off drug pricing controls
Current price caps will stand, but rules on how new caps can be imposed are being tightened